These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6868224)

  • 1. Endocrine treatment of prostatic cancer.
    Pollen JJ
    Urology; 1983 Jun; 21(6):555-8. PubMed ID: 6868224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferred hormone treatment in prostate cancer.
    Hall RR
    Prog Clin Biol Res; 1987; 243B():439-40. PubMed ID: 3659037
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate.
    Huben RP; Murphy GP
    Cancer; 1988 Nov; 62(9):1881-7. PubMed ID: 3139279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine changes after diethylstilbestrol therapy. Effects on prostatic neoplasm and pituitary-gonadal axis.
    Prout GR; Kliman B; Daly JJ; MacLaughlin RA; Griffin PP; Young HH
    Urology; 1976 Feb; 7(2):148-55. PubMed ID: 1246784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The questionable use of hormone therapy in advanced carcinoma of the prostate.
    Murphy GP; Slack NH
    Urol Clin North Am; 1980 Oct; 7(3):631-8. PubMed ID: 6161459
    [No Abstract]   [Full Text] [Related]  

  • 6. Endocrine therapy in the management of advanced prostatic cancer: the case for early initiation of treatment.
    Grayhack JT; Kozlowski JM
    Urol Clin North Am; 1980 Oct; 7(3):639-43. PubMed ID: 7456176
    [No Abstract]   [Full Text] [Related]  

  • 7. Delayed hormonal therapy in advanced prostatic cancer.
    Zungri E; Salvador J; Chéchile G; Diaz I; Martinez E
    Prog Clin Biol Res; 1987; 243B():441-7. PubMed ID: 3659038
    [No Abstract]   [Full Text] [Related]  

  • 8. Hormone therapy of prostatic bone metastases.
    Huben RP
    Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The case for early combined hormonal and cytostatic treatment for metastatic prostatic carcinoma.
    Servadio C
    Prog Clin Biol Res; 1987; 243B():449-53. PubMed ID: 3659039
    [No Abstract]   [Full Text] [Related]  

  • 10. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer.
    Lin BJ; Chen KK; Chen MT; Chang LS
    Urology; 1994 Jun; 43(6):834-7. PubMed ID: 8197647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone.
    Atala A; Amin M; Harty JI
    Urology; 1992 Feb; 39(2):108-10. PubMed ID: 1736500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal treatment of advanced disease: some newer aspects.
    Griffiths K; Eaton CL; Harper ME; Turkes A; Peeling WB
    Semin Oncol; 1994 Oct; 21(5):672-87. PubMed ID: 7939755
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of leuprolide.
    Glode LM; Smith JA
    J Urol; 1987 Jan; 137(1):57-60. PubMed ID: 3098990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma.
    Jordan WP; Blackard CE; Byar DP
    South Med J; 1977 Dec; 70(12):1411-3. PubMed ID: 594790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate.
    Maatman TJ; Gupta MK; Montie JE
    J Urol; 1985 Apr; 133(4):620-1. PubMed ID: 3981712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Testosterone, FSH and LH level in the serum of patients with prostatic neoplasms, treated with female hormones].
    Weidner W; Krause W; Pust R; Engstfeld J; Rothauge CF
    Helv Chir Acta; 1978 Jul; 45(3):287-90. PubMed ID: 701064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
    Peeling WB
    Urology; 1989 May; 33(5 Suppl):45-52. PubMed ID: 2523611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a best castration?
    Griffiths K
    Cancer; 1993 Dec; 72(12 Suppl):3807-9. PubMed ID: 8252495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of endocrine therapy of prostate cancer by assessing tumor markers and hormone parameters. Hormonal "cross-over" treatment of false endocrine independent tumors.
    Kraljić I; Tarle M
    Prog Clin Biol Res; 1987; 243B():521-5. PubMed ID: 3659050
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.